SITE SPECIFIC DOSING OF A BTK INHIBITOR

• US 20180015088A1
• Filed: 12/23/2015
• Published: 01/18/2018
• Est. Priority Date: 12/24/2014
• Status: Abandoned Application

• Current Assignee: Principia Biopharma Inc. (Sanofi )
• Original Assignee: Principia Biopharma Inc. (Sanofi )
• Inventors: NUNN, Philip, BERNER, Bret, MASJEDIZADEH, Mohammad Reza
• Application Number:
  US15/539,094
• Publication Number:
  US 20180015088A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 31/506 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 9/2009 Inorganic compounds
• CPC Class Codes: A61K 9/2013 Organic compounds, e.g. phospholipids, fats
• CPC Class Codes: A61K 9/2018 Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
• CPC Class Codes: A61K 9/2031 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
• CPC Class Codes: A61K 9/2054 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/2086 Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat active cores with a complete drug-free outer coat A61K9/28
• CPC Class Codes: A61K 9/2846 Poly(meth)acrylates
• CPC Class Codes: A61K 9/2853 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/2866 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/2886 having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer of the type active core-drug layer-inactive layer A61K9/209
• CPC Class Codes: A61K 9/4808 characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084
• CPC Class Codes: A61K 9/4866 Organic macromolecular compounds
• CPC Class Codes: A61K 9/5026 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/5047 Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/5073 having two or more different coatings optionally including drug-containing subcoatings
• CPC Class Codes: A61K 9/5078 with drug-free core
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/02 : Immunomodulators

Abstract

Disclosed herein are formulations and methods of site specific administration of Compound (I) or a pharmaceutically acceptable salt thereof. Compound (I) is a potent BTK inhibitor and hence can be useful for the treatment of diseases such as cancer, autoimmune, and inflammatory diseases.

Claims

1. A solid oral dosage form comprising:

(i) 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile

(Compound (I)) and/or a pharmaceutically acceptable salt thereof;

(ii) means for release of Compound (I) and/or said pharmaceutically salt thereof in one or more mammalian intestinal sites chosen from the duodenum, jejunum, ileum, and colon; and

(iii) a pharmaceutically acceptable excipient,

wherein the average systemic bioavailability of Compound (I) as measured by plasma AUC resulting from administration of said solid oral dosage form is from about 150% to about 4000% of the average systemic bioavailability of Compound (I) as measured by plasma AUC resulting from administration of an immediate release dosage form having an equivalent amount of said Compound (I) and/or said pharmaceutically acceptable salt thereof.

2. The solid oral dosage form of claim 1, wherein:

not more than about 10% of the AUC resulting from administration of said solid oral dosage form is contributed within about 1.5 to about 2 hours after dosing when the solid oral dosage form is administered to a mammal in the fasted state.

5. The solid oral dosage form of claim 1, wherein said solid oral dosage form has an onset of release of Compound (I) and/or said pharmaceutically acceptable salt thereof in the terminal portion of the duodenum, the proximal portion of the jejunum, the jejunum, the ileum, the jejuno-ileum, or the colon.

8. The solid oral dosage form of claim 1, wherein not less than about 80% by weight of Compound (1) and/or said pharmaceutically acceptable salt thereof is released from the solid oral dosage form from about twenty minutes to about two hours in a dissolution testing at a pH from about 6.4 to about 7.4.

9. The solid oral dosage form of claim 1 wherein the plasma AUC of Compound (I) resulting from administration of said solid o al dosage form is at least about 200% of the plasma AUC resulting from administration of said immediate release dosage form.

15. The solid oral dosage form of claim 1, wherein the solid oral dosage form releases:

less than about 10% by weight of Compound (I) and/or said pharmaceutically acceptable salt thereof in about 1.5 hours in a dissolution vessel comprising an aqueous solution at a pH of less than about 3;

less than about 10% by weight of Compound (I) and/or said pharmaceutically acceptable salt thereof in about 1.5 hours in a dissolution vessel comprising an aqueous solution at a pH of from about 4.5 to about 5.0; and

not less than about 80% by weight of Compound (I) and/or said pharmaceutically acceptable salt thereoff from about twenty minutes to about two hours in a dissolution vessel comprising an aqueous solution at a pH of from about 6.4 to about 7.4.

21. The solid oral dosage form of claim 1, wherein the solid oral dosage form releases not less than about 80% by weight of Compound (I) and/or said pharmaceutically acceptable salt thereof from about twenty minutes to about two hours in a dissolution vessel comprising a simulated intestinal fluid at a pH of from about 6.4 to about 7.4.

24. The solid oral dosage form of claim 1, wherein Compound (I) is an (E) and (Z) mixture of a mixture of (R) and (S) isomers of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile.

25. The solid oral dosage form of claim 1, wherein Compound (I) is an (E) and (Z) mixture of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile.

26. The solid oral dosage form of claim 1, wherein at least about 85% by weight of Compound (I) and/or said pharmaceutically acceptable salt thereof is the (E) isomer.

28. The solid oral dosage form of claim 1, wherein Compound (I) and/or a pharmaceutically acceptable salt thereof is a substantially pure amorphous form.

29. The solid oral dosage form of claim 1, further comprising an additional pharmaceutically acceptable acid in an amount sufficient to enhance dissolution of Compound (I) and/or said pharmaceutically acceptable salt thereof at a pH of from about 6.4 to about 7.4.

30. The solid oral dosage form of claim 29, wherein the pharmaceutically acceptable acid forms an acidic aqueous solution within the dosage form prior to the release of Compound (I) and/or said pharmaceutically acceptable salt thereof from the solid oral dosage form.

31. The solid oral dosage form of claim 1, further comprising a surfactant present at a concentration above its critical micelle concentration upon disintegration in about 50 mL of aqueous media.

33. The solid oral dosage form of claim 1, wherein the mean particle size of Compound (I) and/or a pharmaceutically acceptable salt thereof is from about 0.3 micron to about 100 microns.

51. The solid oral dosage form of claim 1, wherein the solid oral dosage form is a tablet or a capsule.

52. The solid oral dosage form of claim 1, wherein the pharmaceutically acceptable excipient is chosen from binders, surfactants, diluents, buffers, antiadherents, glidants, disintegrants, antioxidants, antifoaming agents, fillers, flavors, colors, lubricants, sorbents, preservatives, plasticizers, and sweeteners.

55. A method of inhibiting BTK in an mammal comprising administering to the mammal in need of such BTK inhibition a therapeutically effective amount of Compound (I) and/or a pharmaceutically acceptable salt thereof in a solid oral dosage form of claim 1.

56. A method of treating a diseasechosen from an autoimmune disease, cancer, and an inflammatory disease in an mammal, comprising administering to the mammal in need of such disease treatment a therapeutically effective amount of Compound (I) and/or a pharmaceutically acceptable salt thereof in a solid oral dosage form of claim 1.

3. A solid oral dosage form comprising:

(i) 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile

(Compound (I)) and/or a pharmaceutically acceptable salt thereof;

(ii) means for release of Compound (I) and/or said pharmaceutically salt thereof in one or more mammalian intestinal sites chosen from the jejunum, ileum, and colon; and

(iii) a pharmaceutically acceptable excipient,

wherein the average systemic bioavailability of Compound (I) as measured by plasma AUC resulting from administration of said solid oral dosage form is from about 125% to about 2000% of the average systemic bioavailability of Compound (I) as measured by plasma AUC resulting from administration of an intraduodenal release dosage form having an equivalent amount of said Compound (I) and/or said pharmaceutically acceptable salt thereof.

4. The solid oral dosage form of claim 3, wherein

not more than about 10% of the AUG resulting from administration of said solid oral dosage form is contributed within about 1.5 to about 2 hours after dosing when the solid oral dosage form is administered to a mammal in the fasted state.

6-7. -7. (canceled)

10. (canceled)

11. A solid oral dosage form comprising:

(i) 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile

(Compound (1)) and/or a pharmaceutically acceptable salt thereof;

(ii) an enteric coating which releases Compound (I) and/or said pharmaceutically salt thereof in one or more mammalian intestinal sites chosen from the duodenum, jejunum, ileum, and colon; and

(iii) a pharmaceutically acceptable excipient.

12. The solid oral dosage form of claim 11, wherein said solid oral dosage form has an onset of release of Compound (I) and/or said pharmaceutically acceptable salt thereof in the terminal portion of the duodenum, the proximal portion of jejunum, the jejuno-ileum portion of intestine. or the colon of the mammal.

36. The solid oral dosage form of claim 11, wherein said enteric coating is chosen from polymerized gelatin, shellac, methacrylic acid copolymer type CNF, cellulose butyrate phthalate, cellulose hydrogen phthalate, cellulose proprionate phthalate, polyvinyl acetate phthalate (PVAP), cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate, dioxypropyl methylcellulose succinate, carboxymethyl ethylcellulose (CMEC), hydroxypropyl methylcellulose acetate succinate (HPMCAS), and (meth)acrylic acid polymers and copolymers. and said (methacrylic acid copolymers are made from two or more monomers chosen from methyl acrylate, ethyl acrylate, methyl methacrylate, and ethyl methacrylate.

42. The solid oral dosage form of claim 11, wherein the enteric coating is the outermost layer of said solid oral dosage form.

43. The solid oral dosage form of claim 11, wherein the enteric coating is coated with an immediate release coating.

44. The solid oral dosage form of claim 11, further comprising a subcoat below the enteric coating.

45. The solid oral dosage form of claim 44, wherein the subcoat is a water soluble or hydrophilic erodible polymer.

46. The solid oral dosage form of claim 45, wherein the subcoat is a low molecular weight polymer chosen from hydroxymethyl cellulose (HPMC), hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, microcrystalline cellulose, polyvinylpyrrolidiones, polysaccharides, a polysaccharide derivatives, polyvinyl alcohols, polyethylene glycol (PEG), polypropylene glycol (PPG), and a PEG-PPG block copolymer.

47. The solid oral dosage form of claim 44, wherein the subcoat comprises a water insoluble composition comprising:

(i) particles of a water soluble compound capable of forming channels in the water insoluble composition;

or

(ii) water insoluble hydrophilic particles which cause swelling of said subcoat when in contact with an aqueous or gastric media.

48. The solid oral dosage form of claim 47, wherein the water insoluble composition comprises particles of a water soluble compound capable of forming channels in the water insoluble composition causing influx of at least water into the solid oral dosage form and diffusion of Compound (I) and/or said pharmaceutically acceptable salt thereof into the intestine.

49. The solid oral dosage form of claim 47, wherein the water insoluble composition comprises water insoluble hydrophilic particles which cause swelling of said subcoat when in contact with an aqueous or gastric media.

50. The solid oral dosage form of claim 44, wherein the water insoluble composition comprising particles of a water soluble compound capable of forming channels that is impermeable to Compound (I) and/ or said pharmaceutically acceptable salt thereof, wherein the water insoluble composition allows entry of at least water and wherein the water insoluble composition is further capable of swelling and rupturing the subcoat and causing release of Compound (I) and/or said pharmaceutically acceptable salt thereof.

53. The solid oral dosage form of claim 11, wherein the average systemic bioavailability of Compound (I) as measured by plasma AUC resulting from administration of said dosage form is from about 200% to about 4000% of the average systemic bioavailability as measured by plasma AUC, resulting from administration of an immediate release dosage form having an equivalent amount of Compound (I) and/or said pharmaceutically acceptable salt thereof.

54. The solid oral dosage form of claim 11, wherein the average systemic bioavailability of Compound (I) as measured by plasma AUC resulting from administration of said pharmaceutical dosage form is from about 125% to about 2000% of the average systemic bioavailability as measured by plasma AUC, resulting from administration of an intraduodenal release dosage form having an equivalent amount of Compound (I) and/or said pharmaceutically acceptable salt thereof.

13-14. -14. (canceled)

16-20. -20. (canceled)

22-23. -23. (canceled)

27. (canceled)

32. (canceled)

34-35. -35. (canceled)

37-41. -41. (canceled)

57. (canceled)